These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
161 related articles for article (PubMed ID: 18216387)
21. Fen-phen's message to dentists. Hilsen K; Davis S; Iyer P J N J Dent Assoc; 1998; 69(1):37, 47. PubMed ID: 9584764 [No Abstract] [Full Text] [Related]
22. Dose effect of fenfluramine-phentermine in the production of valvular heart disease. Tovar EA; Landa DW; Borsari BE Ann Thorac Surg; 1999 Apr; 67(4):1213-4. PubMed ID: 10320298 [No Abstract] [Full Text] [Related]
24. A dangerous duo? A combination of common diet drugs (fen-phen) may lead to heart valve disease. Boughner DR CMAJ; 1997 Sep; 157(6):705-6. PubMed ID: 9307558 [No Abstract] [Full Text] [Related]
25. Selections from current literature: pharmacological treatment of obesity. Connolly J; Verni C; Trilling J; Kelso E; Shiesha S Fam Pract; 1998 Feb; 15(1):88-93. PubMed ID: 9527304 [No Abstract] [Full Text] [Related]
26. Valve disease due to appetite suppressants (cont'd). Prescrire Int; 1999 Aug; 8(42):115. PubMed ID: 11503830 [TBL] [Abstract][Full Text] [Related]
31. Anorectic therapy and valvular heart disease: a reappraisal. Silvestry FE; St John Sutton M Eur Heart J; 1999 Jul; 20(13):917-20. PubMed ID: 10361039 [No Abstract] [Full Text] [Related]
32. Dose and duration of fenfluramine-phentermine therapy impacts the risk of significant valvular heart disease. Lepor NE; Gross SB; Daley WL; Samuels BA; Rizzo MJ; Luko SP; Hickey A; Buchbinder NA; Naqvi TZ Am J Cardiol; 2000 Jul; 86(1):107-10. PubMed ID: 10867106 [No Abstract] [Full Text] [Related]
33. Obesity and the diet pill dilemma. Healy BP J Womens Health; 1997 Aug; 6(4):391-2. PubMed ID: 9279828 [No Abstract] [Full Text] [Related]
34. Fen-phen and risk of valvular disease. SoRelle R Circulation; 1997 Sep; 96(6):1705-6. PubMed ID: 9323046 [No Abstract] [Full Text] [Related]
35. US journal finds lower risk from diet pills. Josefson D BMJ; 1997 Nov; 315(7119):1329. PubMed ID: 9402766 [No Abstract] [Full Text] [Related]
36. Phen-fen fallout. Financial side effects. Sandrick KM Hosp Health Netw; 1998 Feb; 72(4):90. PubMed ID: 9553524 [No Abstract] [Full Text] [Related]
37. Clinical and echocardiographic follow-up of patients previously treated with dexfenfluramine or phentermine/fenfluramine. Gardin JM; Weissman NJ; Leung C; Panza JA; Fernicola D; Davis KD; Constantine GD; Reid CL JAMA; 2001 Oct 24-31; 286(16):2011-4. PubMed ID: 11667938 [TBL] [Abstract][Full Text] [Related]
38. Valvular abnormalities and cardiovascular status following exposure to dexfenfluramine or phentermine/fenfluramine. Gardin JM; Schumacher D; Constantine G; Davis KD; Leung C; Reid CL JAMA; 2000 Apr; 283(13):1703-9. PubMed ID: 10755496 [TBL] [Abstract][Full Text] [Related]
39. Unusual hypotension and bradycardia in a patient receiving fenfluramine, phentermine, and fluoxetine. Rich JM; Njo L; Roberts KW; Smith KP Anesthesiology; 1998 Feb; 88(2):529-31. PubMed ID: 9477076 [No Abstract] [Full Text] [Related]
40. Report links appetite suppressants with heart disease. FDA encourages reporting of like events. Am J Health Syst Pharm; 1997 Aug; 54(16):1785, 1788. PubMed ID: 9269513 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]